Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - aztreonam lisina - cystic fibrosis; respiratory tract infections - antibatteriċi għal użu sistemiku, - cayston huwa indikat għat-terapija ta 'suppressjoni ta' infezzjonijiet pulmonari kroniċi minħabba pseudomonas aeruginosa f'pazjenti b'fibrożi ċistika (cf) ta '6 snin u aktar. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ecuphar - meloxicam - anti-infjammatorji u anti-rewmatiċi-prodotti - dogs; cats - is-suspensjoni orali:klieb:għas-serħan mill-infjammazzjoni u uġigħ akut kif ukoll kroniku disturbi muskolu-skeletrali. soluzzjoni għall-injezzjoni:klieb:għas-serħan mill-infjammazzjoni u uġigħ akut kif ukoll kroniku disturbi muskolu-skeletrali. tnaqqis ta 'uġigħ u infjammazzjoni wara l-operazzjoni wara kirurġija ortopedika u tessut artab. qtates:għat-tnaqqis tal-uġigħ ta ' wara l-operazzjoni wara ovariohysterectomy u minuri tat-tessuti rotob-kirurġija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - ledipasvir, sofosbuvir - epatite Ċ, kronika - antivirali għal użu sistemiku - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 u 5. għall-vajrus tal-epatite Ċ (hcv) ġenotip-attività speċifika ara sezzjonijiet 4. 4 u 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

viiv healthcare b.v. - abacavir - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - ziagen huwa indikat fit-terapija kombinata antiretrovirali għat-trattament ta 'infezzjoni tal-virus ta' immunodefiċjenza umana (hiv) f'adulti, adolexxenti u tfal. id-dimostrazzjoni tal-benefiċċju ta ' ziagen hija bbażata l-aktar fuq riżultati ta'studji mwettqa darbtejn kuljum, f'pazjenti adulti naΐve għal kura tal-pazjenti fuq terapija kombinata. qabel ma tinbeda kura b'abacavir, screening għall-ġarr ta ' l-allel hla-b*5701 għandhom isiru fi kwalunkwe pazjent infettat bl-hiv, irrispettavament mir-razza. abacavir m'għandux jintuża f'pazjenti magħrufa li jġorru l-allel hla-b*5701.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - aġenti antineoplastiċi - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimikotiċi għal użu sistemiku - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir - epatite Ċ, kronika - antivirali għal użu sistemiku - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 u 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - elvitegravir, kobikistat, emtricitabine, tenofovir alafenamide - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - genvoya huwa indikat għall-kura ta ' l-adulti u l-adolexxenti (korp età 12-il sena u aktar antiki mal-piż mill-anqas 35 kg) infettati bil-virus ta ' immunodefiċjenza umani 1 (hiv 1) mingħajr ebda mutazzjonijiet magħrufa assoċjati mal-reżistenza għall-klassi ta ' inibitur ta ' integrase, emtricitabine jew tenofovir.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - adefovir dipivoxil - epatite b, kronika - inibituri nucleoside u nucleotide reverse transcriptase - hepsera hija indikata għat-trattament ta 'epatite b kronika f'adulti b': mard tal-fwied kumpensat u b'evidenza ta ' replikazzjoni virali attiva, persistenti elevati fis-serum-alanine-aminotransferase (alt) livelli u evidenza istoloġika ta'infjammazzjoni tal-fwied attiva u fibrożi. il-bidu ta 'hepsera it-trattament għandu jiġi kkunsidrat biss meta l-użu ta' sustanza antivirali alternattiva bl-ogħla ġenetiċi barriera għall-reżistenza mhix disponibbli jew ikun xieraq (ara sezzjoni 5. 1);mard tal-fwied dekompensat flimkien mal-tieni aġent mingħajr kross-reżistenza għal hepsera.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

viiv healthcare bv - dolutegravir - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.